1942 - Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants

Co-Author(s)

• AH

  Ahuva Hanau, BS

  Research Assistant
  Policy Analysis Inc.
  Brookline, Massachusetts, United States
• KS

  Kimberly M. Shea, Ph.D., M.P.H.

  Value and Evidence Lead
  Pfizer Inc.
  Newton, Massachusetts, United States
• DW

  Derek Weycker, Ph.D.

  Senior Health Economist
  Policy Analysis Inc.
  Chestnut Hill, Massachusetts, United States
• MA

  Mark Atwood, MS

  Policy Analysis Inc (PAI)
  Boston, Massachusetts, United States
• EQ

  Erin Quinn, BS

  Senior Research Associate
  Policy Analysis Inc.
  Boston, Massachusetts, United States
• EK

  Emily Kutrieb, B.A.

  Analyst
  Policy Analysis Inc.
  Boston, Massachusetts, United States
• JA

  Jessica E. Atwell, PhD, MPH

  Pfizer
  Flagstaff, Arizona, United States
• AC

  Alejandro D. Cane, MD, PhD

  North America Vaccines Medical Scientific Affairs Lead
  Pfizer
  Collegeville, Pennsylvania, United States
• BG

  Bradford J. Gessner, M.D., M.P.H.

  Vice President Global Medical Lead for Respiratory Vaccines
  Pfizer Biopharma Group
  Collegeville, Pennsylvania, United States
• SP

  Sarah J. Pugh, PhD, MPH

  Senior Director, US Medical Affairs
  Pfizer, Inc.
  Collegeville, Pennsylvania, United States

Presenting Author(s)

• 

  Amy W. Law, PharmD

  Director, Global Value & Evidence
  Pfizer, Inc.
  New York, NY, United States

  Slides